HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Compare relative returns, fundamentals, and sector rankings head-to-head.

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Keros Therapeutics, Inc.

Contributing Author

Recent Articles by Keros Therapeutics, Inc.

Jun-01
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference KROS GlobeNewswire
May-14
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results KROS -8.34% GlobeNewswire
Mar-09
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference KROS GlobeNewswire
Mar-09
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS KROS GlobeNewswire
Mar-04
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results KROS -14.96% KROS GlobeNewswire
Feb-26
Keros Therapeutics Appoints Charles Newton to its Board of Directors KROS -5.59% KROS GlobeNewswire
Feb-18
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences KROS GlobeNewswire
Nov-20
Keros Therapeutics Announces Final Results of Tender Offer KROS GlobeNewswire
Nov-19
Keros Therapeutics Announces Preliminary Results of Tender Offer KROS GlobeNewswire
Nov-05
Keros Therapeutics Reports Third Quarter 2025 Financial Results KROS GlobeNewswire
Oct-20
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares KROS +9.83% GlobeNewswire
Oct-15
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital KROS GlobeNewswire
Sep-08
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting KROS GlobeNewswire
Aug-28
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences KROS GlobeNewswire
Aug-20
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy KROS GlobeNewswire
Aug-06
Keros to Exclusively Prioritize the Clinical Advancement of KER-065 KROS -7.29% KROS GlobeNewswire
Aug-06
Keros Therapeutics Reports Second Quarter 2025 Financial Results KROS -7.29% KROS GlobeNewswire
Jul-17
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept KROS GlobeNewswire
Jun-09
Keros Announces Return of $375 Million in Excess Capital to Stockholders KROS -6.32% GlobeNewswire
Jun-06
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference KROS GlobeNewswire
May-29
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring KROS GlobeNewswire
May-27
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees KROS GlobeNewswire
May-19
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value KROS GlobeNewswire
May-12
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference KROS GlobeNewswire
May-08
Keros Reinforces Commitment to Maximizing Stockholder Value KROS GlobeNewswire
May-06
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results KROS -5.46% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)